Skip to content

A Randomized Controlled Study for Autologous DC-CIK Sequential Combined With Entecavir in the Treatment of Chronic Hepatitis B Virus

A Randomized Controlled Study for Autologous DC-CIK Sequential Combined With Entecavir in the Treatment of Chronic Hepatitis B Virus

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900022309
Enrollment
Unknown
Registered
2019-04-04
Start date
2019-09-01
Completion date
Unknown
Last updated
2019-04-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Hepatitis B

Interventions

1:DC-CIK combined with ETV
2:ETV

Sponsors

Mengchao Hepatobiliary Hospital of Fujian Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1.Patients aged 18 to 60 years, No gender limitation; 2.Hepatitis B surface antigen positive >6 months,the quantify of HBsAg 4.0×10^9/L, Hb > 120 g/L, PLT > 100×10^9/L; 5.HBV DNA less than 500IU/L; 6.The patients volunteer to join in the trial and sign the informed consents.

Exclusion criteria

Exclusion criteria: 1.Liver Cirrhosis certained by ultrasound or CT scanning should be exclused. 2.Pregnant or lactating women; Disabilitie persons sprescribed by law (such as:blind, deaf, dumb, mentally retarded, physically disabled) or suffering from mental diseases; Taking drugs or adverse drug abuse are exclucive also. 3.HBV combining with alcoholic hepatitis, drug-induced liver damage and other metabolic liver diseases. 4.Autoimmune deficiency disease,or accepted tissue transplant. 5.Infected HAV,HCV,HDV. 6.Suffer from hcc and other malignant diseases by HBV. 7.The investigator determines that any factors that the patients are not suitable for the study.

Design outcomes

Primary

MeasureTime frame
negative conversion rate and seroconversion rate of HBeAg;

Secondary

MeasureTime frame
HBsAg;

Countries

China

Contacts

Public ContactXiaolou Li
lixiaolou2014@163.com+86 13405906054

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026